Get the weekly note

Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.

ETFIQetfiq.com · independent ETF data

FNDX vs XBI: how they differ

FNDX and XBI hold 2% of their weight in the same names, and XBI returned more over the year.

Schwab Fundamental U.S. Large Company ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.

What they hold in common

By the books each fund has filed, FNDX and XBI hold 2% of their money in the same securities at the same weight.

Positions FNDX and XBI both hold, largest shared weight first
HoldingFNDXXBI
AbbVie Inc0.53%1.04%
Amgen Inc0.35%1.00%
Gilead Sciences Inc0.32%0.97%
Moderna Inc0.15%1.41%
Regeneron Pharmaceuticals Inc0.13%0.96%
Biogen Inc0.12%1.03%
Vertex Pharmaceuticals Inc0.09%1.06%
United Therapeutics Corp0.03%0.93%
Incyte Corp0.01%1.00%
Largest positions each one holds and the other does not
Only in FNDXOnly in XBI
Apple Inc 4.64%Apogee Therapeutics Inc 1.49%
Intel Corp 2.57%Twist Bioscience Corp 1.41%
Alphabet Inc 2.38%Oruka Therapeutics Inc 1.38%
Microsoft Corp 2.33%Kymera Therapeutics Inc 1.36%
Exxon Mobil Corp 2.29%Viking Therapeutics Inc 1.31%
Alphabet Inc 1.90%Praxis Precision Medicines Inc 1.29%
Amazon.com Inc 1.86%Erasca Inc 1.27%
Micron Technology Inc 1.60%Revolution Medicines Inc 1.21%

Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and May 31, 2026.

FNDX and XBI on the fields both publish, as of Sep 12, 2026. Source: ETFIQ.
FNDX
Schwab Fundamental U.S. Large Company ETF
XBI
State Street(R) SPDR(R) S&P(R) Biotech ETF
Where it sitsCore index fundCore index fund
IssuerSchwabState Street
What it isFundamental U.S. Large CompanySPDR S&P Biotech
Total return, 1 year+26.1%+64.0%
S&P 500 over the same days+17.5%+17.5%
Gap to the S&P 500+8.6 pts+46.5 pts
Expense ratio0.25%0.35%
Already in the S&P 50091.2%8.5%
Holdings733150

FNDX in plain words

FNDX is an index equity fund tracking the Fundamental U.S. Large Company. Over the year to Sep 11, 2026 it returned +26.1% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.25% a year. By its holdings filed for May 31, 2026, 91% of the fund by weight is stocks the S&P 500 also holds, across 733 positions, with the top ten at 22.5%.

XBI in plain words

XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.

Questions people ask

Which returned more over the last year, FNDX or XBI?
In the year to Sep 12, 2026, with distributions reinvested, FNDX returned +26.1% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
Which is cheaper, FNDX or XBI?
FNDX charges 0.25% a year and XBI charges 0.35%, so FNDX is cheaper. Fees come from each fund's prospectus.
How much do FNDX and XBI overlap with the S&P 500?
By their latest filed holdings, 91% of FNDX and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.

Other comparisons

Where to next

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

FNDX against XBI, ETFIQ, data as of Sep 12, 2026. Every figure is arithmetic on a named public source; the method is at etfiq.com/methodology. A comparison is not a recommendation.

Cite this page. ETFIQ, FNDX against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/FNDX-XBI Free to use with attribution; the underlying files are at Open data.

A comparison is not a recommendation. Standards and sources